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A B S T R A C T
Background: The treatment of borderline personality disorder (BPD) has been examined extensively in adults up
to the age of fifty in the past quarter of a century, but there is still a world to discover in treating BPD in older
adults. The aim of the study is to investigate the effectiveness of schema therapy in older adults with BPD.
Methods/design: A multiple baseline design is used in which participants are randomly assigned to baseline
length. The primary outcome measure is assessed weekly and consists of the credibility of negative core beliefs.
Secondary outcome measures are quality of life, psychological distress, early maladaptive schemas, schema
modes, severity of BPD symptoms and meeting the criteria for BPD. Ten older adults (age > 60 years) with BPD
are treated with schema therapy, with weekly sessions during one year. This treatment phase is preceded by a
baseline phase varying from 4 to 8 weeks. After treatment, there is a 6-month follow-up phase with monthly
booster sessions.
Discussion: To our knowledge, this is the first empirical study of the effectiveness of psychotherapeutic treatment
for BPD in older adults. Because of the different manifestation of BPD in later life, besides section II DSM-5
criteria, the alternative, dimensional model for personality disorders of DSM-5 is used to assess BPD in older
adults.
Trial registration: The Netherlands National Trial Register NTR7107. Registered 11 March 2018.
1. Introduction
Borderline personality disorder (BPD) is a lifelong pattern of in-
stability in interpersonal relationships, self-image, and affect [1]. It also
features impulsivity and self-harming behavior. The prevalence of BPD
is estimated to be around 1–2% [2]. In older age groups (> 60 years)
the prevalence of BPD may decrease [3]. Although the prevalence can
be lower, there is still a substantial group of older adults that meet the
criteria for BPD, and core features of BPD, especially emotional dysre-
gulation and disturbed interpersonal relationships persist into old age
[4]. These BPD features are associated with psychosocial impairment in
older adults [5]. BPD in later life differs in presentation from that seen
in younger adults [6]. Lower levels of impulsivity and identity dis-
turbance are observed, in contrast with increased feelings of emptiness,
and somatic symptoms and complaints. Also, the self-harming behavior
may change, e.g., non-compliance with a medical treatment instead of
auto-mutilation. As a consequence of the changes in the manifestation
of BPD in later life, it has proven difficult to diagnose personality dis-
orders adequately in older adults [7,8]. In large-scale item response
theory analyses, less personality disorder criteria were identified in
older people as compared to younger people [9] and even 29% of
personality disorder criteria showed unacceptable high measurement
errors in older people [9]. Thus, the description of BPD-traits in the
Diagnostic and Statistical Manual of Mental Disorders [2] might lead to
an underestimation of the ‘true’ prevalence of BPD at older age. This
calls for a broader view on the behavioral expression of borderline
pathology in older adults.
An alternative approach for personality disorders is described in
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section III of the DSM-5 [2]. In this alternative model, the diagnosis of
personality disorders is characterized by impairments in personality
functioning (Criterion A) and pathological personality traits (Criterion
B), which are dimensionally assessed. Dimensional models like this
alternative DSM-5 model seem to be more fruitful than the categorical
ones, like section II of DSM-5, for assessing personality pathology in
later life [8,10]. Increased scores on the pathological traits negative
affectivity, disinhibition, and psychoticism are aspects of this alter-
native DSM-5 model that are correlated with the criteria of the DSM-5
section II model for BPD [11]. The construct validity of both the DSM-5
section III maladaptive trait domains [12] and the Severity Indices of
Personality Functioning–Short Form (SIPP-SF) have been demonstrated
in older adults as a measure to assess personality functioning [13]
Therefore, in the current study we incorporate a broad diagnostic view
in assessing BPD in older adults, employing both the current, catego-
rical and the alternative, dimensional approaches, preventing missed
diagnoses and refining the diagnostic process.
Research shows that there are different ways to adequately treat
BPD, among which are dialectical behavior therapy, systems training
for emotional predictability and problem-solving, mentalization-based
treatment, transference-focused psychotherapy, and schema therapy
[14]. Schema therapy (ST) is a form a treatment that seems to connect
to the psychotherapy expectations of older adults, because it in-
corporates psychoeducation and because of its structured, skill-enhan-
cing and problem-focused features [15]. ST is an integrative treatment,
which draws on the cognitive-behavioral, attachment, psychodynamic,
and emotion-focused traditions and can be adjusted for treating BPD
[16]. In this treatment model, early maladaptive schemas (EMS) are
considered core elements of personality disorders. EMS are self-de-
feating emotional and cognitive patterns established in childhood and
repeated throughout life [17]. When a maladaptive schema is activated,
associated painful emotions arise; early in life, patients have developed
coping strategies to deal with these emotions. A schema mode is a
combination of activated schemas and coping strategies, which de-
scribes the current emotional, cognitive, and behavioral state a patient
is in. Modes are states which can change quickly, while schemas are
more like traits, rigid and enduring. Cognitive interventions, experi-
ential techniques, and the therapeutic relationship are important ele-
ments in schema therapy. The goal of treatment is to decrease the im-
pact of the EMS and to replace maladaptive schema modes with more
healthy alternatives so that patients succeed in getting their core
emotional needs met [18].
ST has been proven effective in treating younger and middle aged
adults with personality disorders [19,20]. There is emerging proof that
ST can also be effective for older adults with personality disorders
[15,21]. A recent study showed that ST is an effective treatment for
older adults with cluster C personality disorders [21]. This study was
the first test of the effectiveness of any psychotherapy for personality
disorders in older adults, using a multiple baseline design. Results re-
vealed significant linear trends during the treatment phase, but not
during baseline and follow-up. Seven of eight patients remitted from
their personality disorder diagnosis.
The aim of the current study is to investigate whether ST can be an
effective treatment for older adults with BPD. Successful treatment of
BPD in older adults can improve well-being later in life [22] and can
reduce the complications of treatment of other psychiatric disorders
[23].
2. Present study
The aim of this study is to investigate the effectiveness of individual
ST as a treatment for older adults with BPD. The research question is
whether older patients with BPD benefit from ST. The primary objective
is to study the effect of ST on the strength of negative core beliefs in
older adults with BPD. We hypothesize that ST diminishes the strength
of these negative core beliefs.
Secondary objectives are improvement of quality of life, reducing
psychological distress, decreasing EMS and maladaptive schema modes,
and reducing the severity of BPD symptoms. In particular, we hy-
pothesize that participants will no longer meet the criteria for BPD,
employing both the categorical and the alternative model for person-
ality disorders of DSM-5.
3. Methods
3.1. Study design and procedure
This study is a multiple baseline case series design [24]. We chose
this design for several reasons. A multiple-baseline case series design
offers experimental control over time versus intervention effects, which
is an important advantage over an open trial. Like an RCT, a multiple-
baseline design can demonstrate significant change and that this change
is the result of the intervention and not of time [25]. Secondly, an
advantage of this design over a randomized controlled trial (RCT) is
that this design requires fewer participants; participants act as their
own controls, thus increasing power [26].
A multiple-baseline design requires a dependent variable that is
frequently assessed and highly sensitive to change, in order to assess the
time and intervention effects [25]. Such a variable should represent a
core aspect of the disorder that is addressed by the treatment. The
frequent assessments make it possible to distinguish time from treat-
ment effects and allow that each case is its own control. In other words,
the frequent assessments of the central variable compensate for the
small number of participants. As central variable, we chose the strength
of belief participants have in their personal core beliefs, which they
view as central to their PD problems. This idiosyncratic measure re-
presents the EMS that are assumed to underlie the patient's personality
disorder problems according to the schema therapy model [16].
The design consists of three phases. First, a baseline phase varying
in length from four to eight weeks. No therapeutic interventions will be
applied during this phase. The second phase is the treatment phase and
consists of ST for BPD according to the model of Young and colleagues
[17]. Precise methods for the treatment of BPD using ST is described in
Arntz & van Genderen [27]. The third and final phase is a six months
follow-up with monthly booster sessions.
The length of the baseline phase is randomized across participants
to increase the internal validity. Randomization of participants over
variations in baseline length increases the experimental control over
differentiating time from treatment effects. Baseline varies between
four to eight weeks and will be randomly assigned by an independent
colleague using a lottery system. The lottery system consists of five
different possible outcomes (4, 5, 6, 7, and 8 weeks). Each different
outcome is represented two times, making a total of ten outcomes.
There is no replacement after each draw, so different baseline lengths
are evenly distributed among participants.
The duration of the treatment phase is 52 weeks and is estimated to
be sufficient to accomplish meaningful results [21]. During the treat-
ment phase, the therapist decides when to introduce the different
techniques, according to the ST model [16,27] and participants’ case
conceptualization.
The follow-up phase lasts six months and includes monthly booster
sessions in which the aim is to maintain the acquired ST knowledge and
skills.
3.2. Participants and screening procedure
The participants are ten patients from the department of geriatric
psychiatry of Breburg and from the department of geriatric psychiatry
of Mondriaan, both mental health institutes in the Netherlands.
Four inclusion criteria must be met: 1) a primary diagnosis of BPD,
assessed with the Structured Clinical Interview for DSM-5 Personality
disorders (SCID-5-P; [28]). In this semi-structured interview
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experiences in early adulthood will be emphasized in order to increase
the validity of the diagnosis. Participants who meet the subthreshold
level of the diagnostic criteria of BPD are also included, given the dif-
ferent behavioral expression of BPD in older adults (as argued in the
introduction), but only if there are increased scores on the traits ne-
gative affectivity, disinhibition, and psychoticism of the Personality
Inventory for DSM-5 (PID-5; [29]). These three traits of the alternative
model of DSM-5 are correlated with the DSM-5 section II diagnosis of
BPD [30]. A mean score of 2 or higher is seen as increased [31]. The
PID-5 will be administered to both the participant and a close relative;
2) absence of chronic somatic comorbidity which seriously affects daily
life functioning, demonstrated by a minimum Barthel-score of 15 [32];
3) minimum age of 60 years; 4) willingness to participate in the study.
Exclusion criteria are severe depression, bipolar disorder, psychotic
disorder (other than transient stress-related psychosis, if this overlaps
with criterion 9 of BPD), IQ under 80, substance dependence that needs
clinical detoxification (participation is possible after successful detox-
ification), and neurocognitive disorder expressed by a MMSE-score
below 25 [33]. All these factors are taken into account during the
multidisciplinary clinical assessment at the particular mental health
institute. These factors are labeled exclusion criteria in consideration of
their possible disturbing effect on treatment. No other treatment is al-
lowed and preferably the use of psychiatric medication is kept constant
during the study and is at least monitored using single session regis-
tration forms.
Patients who meet these criteria are approached by the first author
to participate in the study.
3.3. Instruments and outcome measures
3.3.1. Primary outcome measures
The primary outcome measure is the weekly assessed credibility of
idiosyncratic beliefs. These beliefs are evoked by a semi-structured
procedure during the baseline phase. Each participant formulates three
to five idiosyncratic, dysfunctional beliefs they consider to be central to
their personality disorder. Participants will rate the degree they believe
each statement on a visual analog scale (VAS) from 0 to 100% cred-
ibility. The core beliefs are rated weekly during baseline, treatment and
follow-up phases, at the start of each session. The therapist will not be
present when participants fill in the VAS to assure integrity. Filled-in
forms will be given to the therapist in a closed envelope and passed on
to the research team.
3.3.2. Secondary outcome measures
Quality of life is assessed by the Dutch brief version of the World
Health Organization Quality of Life (WHOQOL-BREF; [34]). The
WHOQOL-BREF is a self-report measure that consists of 26 items, which
are rated on a 5-point Likert scale. Research in two samples of older
adults, with mean ages of 73 and 76 years, showed good reliability and
satisfactory construct validity [35].
Psychological distress is measured by the Brief Symptom Inventory*
(BSI; [36]). The BSI is a 53-item self-report measure, which is rated on a
5-point rating scale. The reliability and validity of the BSI are good,
with reliability coefficients ranging from 0.68 to 0.91 [37], and the
Dutch version of the BSI has been validated in older adults [38].
Early maladaptive schemas are measured with the Dutch Young
Schema Questionnaire* (YSQ; [39]). The questionnaire consists of 16
subscales and includes 205 items, which are phrased as negative core
beliefs and rated along a 6-point Likert scale. In a clinical sample with a
mean age of 33.9 years (range 18–74) the YSQ showed good reliability
and convergent and discriminant validity [40]. The YSQ measures EMS
scales equally across age [41].
Schema modes are assessed by the Dutch Short Schema Mode
Inventory* [42]. It consists of 14 subscales and includes 118 items
which must be rated on a 6-point Likert scale. This questionnaire has
acceptable internal consistencies (Cronbach α′s from 0.79 to 0.96) and
moderate construct validity [42].
Current severity of BPD is assessed with the Dutch version of the
BPDSI [43], a semi-structured interview which assesses the frequency
and severity of BPD symptoms during the last three months. The BPDSI
consists of nine sections, one for each of the DSM-criteria for BPD and
appears reliable and internally consistent [43].
Personality Disorder Diagnoses are assessed with the SCID-5-P* [28],
a semi-structured interview for DSM-5 personality disorder diagnoses.
Personality disorder-criteria are rated on a 3-point scale as absent, sub-
threshold or threshold. Reliability and validity are not yet available, but
are expected to be similar to the Dutch version of the Structured Clin-
ical Interview for DSM-IV Axis II disorders [44] as both instruments are
almost similar. Inter-rater agreement appeared excellent in adults with
an average age of 35.5 years (range 18–61), with a mean value of Co-
hen's kappa of .84 [45].
Personality functioning is measured with the Severity Indices of
Personality Problems short form* (SIPP-SF; [46]), a self-report ques-
tionnaire aiming to measure the severity of the generic and changeable
components of personality disorders. The SIPPF-SF consists of 60-items
and five domains: self-control, identity integration, responsibility, re-
lational capacities, and social concordance. Participants are asked to
answer on a 4-point scale to what extent they agree with the statement
presented, referring to the past three months. A study concerning the
construct validity of the SIPP-SF for older adults demonstrated a
structure of five higher order domains of personality functioning [13].
Dimensional assessment of pathological personality traits: The
Personality Inventory for DSM-5* is a 220-item self-report ques-
tionnaire developed to assess personality traits in line with the di-
mensional perspective of personality pathology as advocated in Section-
III of DSM-5 [47]. The original five-factor structure of the PID-5 has
been confirmed in the Dutch version, and it has adequate reliability and
convergent and discriminant validity [29].
These secondary outcomes will be measured four times: at the start
of treatment and after six, twelve, and eighteen months, except for the
SCID-5-P which will be administered twice (before and directly after
the treatment phase).
3.4. Ethical issues and treatment integrity
The study procedure was reviewed and approved by the internal
ethical committees of Breburg and Mondriaan, and METC Brabant, an
independent ethical committee. All participants will be informed by the
principal investigator, both orally and by letter, and sign an informed
consent before the start of the study. Most of the measures used for
inclusion and study outcomes are a standard part of routine outcome
monitoring and standard diagnostic procedures at Breburg and
Mondriaan (these measures are marked with an asterisk [*]). Two di-
agnostic instruments are added to this standard battery: the World-
Health-Organization-Quality-Of-Life, brief version (WHOQOL-BREF,
which measures quality of life) and the Borderline Personality Disorder
Severity Index (BPDSI, which assesses the frequency and severity of
BPD symptoms). ST can be considered a safe treatment as it has been
found effective for BPD in younger adults, and it is increasingly used as
a treatment in older adults in clinical practice; moreover, the effec-
tiveness of ST has been established in older adults with cluster C per-
sonality disorders [21].
Treatment integrity is secured in five ways. All therapists in this
study are well trained and educated in ST and are (candidate) members
of the Dutch schema therapy association. Second, therapists can consult
each other. Third, all therapists receive a training in which the study
design and ways of reporting the sessions are made explicit.
Furthermore, each session is registered using a tailor-made session re-
gistration form to describe the applied ST intervention. And finally, a
random sample of five recorded sessions per therapy is rated for ad-
herence to ST, using the Schema Therapy Rating Scale [48].
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4. Statistical and power analysis
A multiple baseline design is, just like an RCT, capable of demon-
strating the occurrence of change over time as a result of an interven-
tion [49]. The fact that participants serve as their own controls and that
the primary outcome is measured frequently can compensate for the
potential loss of power. As an indication, it is possible to detect a large
effect size (d > 1.5; power > .80) with four participants with twenty
measurements each [24]. Due to the design of the current study, it is to
be expected that the number of participants and measurements neces-
sary to obtain such power will be exceeded.
Statistical analysis will be performed using a time series analysis
based upon mixed regression. This type of analysis is possible because
of the sufficient length of the treatment phase [25,26]. Mixed regres-
sion analysis will be used to explore the differences between treatment
and the follow-up phase compared to the baseline phase.
5. Discussion
To our knowledge, this is the first empirical study of the effective-
ness of psychotherapeutic treatment for BPD in older adults. In recent
years there has been a shift in thinking about treatment possibilities in
older adults with personality disorders [50]. Therapeutic nihilism has
been replaced by a more optimistic and promising view that psy-
chotherapy can make a difference for older adults who suffer from
personality disorders and that it is possible to enhance their quality of
life and sense of meaning in life. The treatment of BPD in younger
adults has been examined extensively in the past quarter of a century,
but there is still a world to discover in treating BPD in older adults. This
study is a first step in the road ahead.
As stated, it is not straightforward to diagnose BPD in older adults. It
is a challenging procedure because of the different manifestation of BPD
in later life, and the fact that the DSM-description of BPD-traits might
lead to an underestimation of the ‘true’ prevalence of BPD at older age.
We have also employed a more dimensional model of BPD, in which,
besides section II DSM-5 criteria, the pathological personality traits of
the alternative model for personality disorders in section III of DSM-5
are used to diagnose BPD in older adults, for cases that are subthreshold
BPD according to the criteria of section II of DSM-5. This diagnostic
approach is not yet common in studies into BPD in younger age groups,
but we think this is helpful to achieve comprehensive and meaningful
results in studying BPD in later life.
A possible limitation of the present study is the length of treatment,
which is set at 52 weekly sessions, followed by six monthly booster
sessions. There is a great variation in the treatment dosage among
different studies concerning ST and personality disorders, with the
number of treatment sessions ranging from 78 up to 300 sessions
[19,20,51]. The length of treatment in the present study is based on the
fact that more recent studies show a reduction in length of treatment
compared to earlier studies [19,52], and 52 sessions appeared effective
in older adults with cluster C personality disorders [21].
A possible criticism could be the small sample size (N=10), in
particular compared to RCT studies. Yet the construction of a multiple
baseline design makes it possible to acquire sufficient power to de-
monstrate treatment effects, even with a small N.
The results of this study will contribute to our understanding of
treating BPD in older adults with ST and intends to provide beneficial
information for the development of therapeutic interventions for older
adults with BPD.
Trial status
The trial started in August 2018 and data collection is expected to
continue until September 2020.
Competing interests
The authors declare that they don't have competing interests.
This research did not receive any specific grant from funding
agencies in the public, commercial, or not-for-profit sectors.
References
[1] M.C. Zanarini, F.R. Frankenburg, D.B. Reich, G. Fitzmaurice, Attainment and sta-
bility of sustained symptomatic remission and recovery among borderline patients
and Axis II comparison subjects: a 16-year prospective follow-up study, Am. J.
Psychiatry 169 (2012) 476–483.
[2] M. ten Have, R. Verheul, A. Kaasenbrood, S. van Dorsselaer, M. Tuithof,
M. Kleinjan, R. de Graaf R, Prevalence rates of borderline personality disorder
symptoms: a study based on The Netherlands Mental Health Survey and Incidence
Study-2, BMC Psychiatry 16 (2016) 249.
[3] T.F. Oltmanns, M.M. Rodrigues, Y. Weinstein, M.E. Gleason, Prevalence of per-
sonality disorders at midlife in a community sample: disorders and symptoms re-
flected in interview, self, and informant reports, J. Psychopathol. Behav. Assess. 36
(2014) 177–188.
[4] F. Gutiérrez, G. Vall, J.M. Peri, E. Baillés, L. Ferraz, M. Gárriz, X. Caseras,
Personality disorder features through the life course, J. Pers. Disord. 26 (2012)
763–774.
[5] A.D. Powers, M.E.J. Gleason, T.F. Oltmanns, Symptoms of borderline personality
disorder predict interpersonal (but not independent) stressful life events in a
community sample of older adults, J. Abnorm. Psychol. 122 (2013) 469–474.
[6] J. Beatson, J.H. Broadbear, H. Sivakumaran, K. George, E. Kotler, F. Moss, S. Rao,
Missed diagnosis: the emerging crisis of borderline personality disorder in older
people, Aust. N. Z. J. Psychiatr. 50 (2016) 1139–1145.
[7] S. Balsis, C.M. Woods, M.E. Gleason, T.F. Oltmanns, Overdiagnosis and under-
diagnosis of personality disorders in older adults, Am. J. Geriatr. Psychiatry 15
(2007) 742–753.
[8] P.J. Cruitt, T.E. Oltmanns, Age-related outcomes associated with personality pa-
thology in later life, Curr. Opin. Psychol. 21 (2018) 89–93.
[9] S. Balsis, C.M. Woods, M.E. Gleason, T.F. Oltmanns, An item response theory
analysis of DSM-IV personality disorder criteria across younger and older age
groups, Psychol. Aging 22 (2007) 171–185.
[10] S.P.J. van Alphen, G. Rossi, D.L. Segal, E. Rosowsky, Issues regarding the proposed
DSM-5 personality disorders in geriatric psychology and psychiatry, Int.
Psychogeriatr. 25 (2013) 1–5.
[11] B. Bach, J. Anderson, E. Simonsen, Continuity between interview-rated personality
disorders and self-reported DSM–5 traits in a Danish psychiatric sample, Personality
Disorders: Theory, Research, and Treatment, vol. 8, 2017, pp. 261–267.
[12] I. Debast, G. Rossi, S.P.J. van Alphen, Construct validity of the DSM-5 section III
maladaptive trait domains in older adults, J. Pers. Disord. 31 (2017) 671–688.
[13] G. Rossi, I. Debast, S.P.J. van Alphen, Measuring personality functioning in older
adults: construct validity of the severity Indices of personality functioning–short
form (SIPP-SF), Aging Ment. Health 21 (2017) 703–711.
[14] I.A. Cristea, C. Gentili, C.D. Cotet, D. Palomba, C. Barbui, P. Cuijpers, Efficacy of
psychotherapies for borderline personality disorder, JAMA Psychiatry 74 (2017)
319–328.
[15] A.C. Videler, G. Rossi, M. Schoevaars, C.M. van der Feltz-Cornelis, S.P.J. van
Alphen, Effects of schema group therapy in older outpatients: a proof of concept
study, Int. Psychogeriatr. 26 (2014) 1709–1717.
[16] S.H. Kellogg, J.E. Young, Schema therapy for borderline personality disorder, J.
Clin. Psychol. 62 (2006) 445–458.
[17] J.E. Young, J.S. Klosko, M.E. Weishaar, Schema Therapy: A Practitioner's Guide,
Guilford Press, New York, 2003.
[18] E. Rafaeli, D.P. Bernstein, J. Young, Schema Therapy: the CBT Distinctive Features
Series, Routledge, London and New York, 2010.
[19] L.L.M. Bamelis, S.M.A.A. Evers, P. Spinhoven, A. Arntz, Results of a multicenter
randomized controlled trial of the clinical effectiveness of schema therapy for
personality disorders, Am. J. Psychiatry 171 (2014) 305–322.
[20] J. Giesen-Bloo, R. van Dyck, P. Spinhoven, W. van Tilburg, C. Dirksen, T. van Asselt,
I. Kremers, M. Nadort, A. Arntz, Outpatient psychotherapy for borderline person-
ality disorder: randomized trial of schema-focused therapy vs transference-focused
psychotherapy, Arch. Gen. Psychiatr. 63 (2006) 649–658.
[21] A.C. Videler, S.P.J. van Alphen, R.J. van Royen, C.M. van der Feltz-Cornelis,
G. Rossi, A. Arntz, Schema therapy for personality disorders in older adults: a
multiple-baseline study, Aging Ment. Health 22 (2018) 738–747.
[22] E. Rosowsky, B. Gurian, Impact of borderline personality disorder in late life on
systems of care, Hosp. Community Psychiatry 43 (1992) 386–389.
[23] R.C. Abrams, G.S. Alexopoulos, L.A. Spielman, E. Klausner, T. Kakuma, Personality
disorder symptoms predict declines in global functioning and quality of life in el-
derly depressed patients, Am. J. Geriatr. Psychiatry: Official J. Am. Assoc. Geriatr.
Psychiatry 9 (2001) 67–71.
[24] J. Ferron, C. Sentovich, Statistical power of randomization tests used with multiple-
baseline designs, J. Exp. Educ. 70 (2002) 165–178.
[25] I. Bulté, P. Onghena, Randomization tests for multiple-baseline designs: an exten-
sion of the SCRT-R package, Behav. Res. Methods 41 (2009) 477–485.
[26] A.E. Kadzin, Single Case Research Design: Methods for Clinical and Applied
Settings, second ed., Oxford University Press, New York, 2010.
[27] A. Arntz, H. van Genderen, Schema Therapy for Borderline Personality Disorder,
D.A. Khasho et al. Contemporary Clinical Trials Communications 14 (2019) 100330
4
John Wiley & Sons, Hoboken, 2011.
[28] M.B. First, J.B. Williams, L.S. Benjamin, R.L. Spitzer, SCID-5-PD: Structured Clinical
Interview for DSM-5 Personality Disorders, VA, American Psychiatric Association
Publishing, Arlington, 2016.
[29] T. Bastiaens, L. Claes, D. Smits, B. de Clercq, F. de Fruyt, G. Rossi, M. de Hert, The
construct validity of the Dutch personality inventory for DSM-5 personality dis-
orders (PID-5) in a clinical sample, Assessment 23 (2016) 42–51.
[30] B. Bach, J. Anderson, E. Simonsen, Continuity between interview-rated personality
disorders and self-reported DSM–5 traits in a Danish psychiatric sample, Personality
Disorders: Theory, Research, and Treatment, vol. 8, 2017, p. 261.
[31] B. Bach, K. Markon, E. Simonsen, R.F. Krueger, Clinical utility of the DSM-5 al-
ternative model of personality disorders: six cases from practice, J. Psychiatr. Pract.
21 (2015) 3–25.
[32] C. Collin, D.T. Wade, S. Davies, V. Horne, The barthel ADL index: a reliability study,
Disabil. Rehabil. 10 (1988) 61–63.
[33] M.F. Folstein, S.E. Folstein, P.R. McHugh, “Mini-mental state”: a practical method
for grading the cognitive state of patients for the clinician, J. Psychiatr. Res. 12
(1975) 189–198.
[34] F.J. Trompenaars, E.D. Masthoff, G.L. van Heck, P.P. Hodiamont, J. de Vries,
Content validity, construct validity, and reliability of the WHOQOL-Bref in a po-
pulation of Dutch adult psychiatric outpatients, Qual. Life Res. 14 (2005) 151–160.
[35] G. Low, A.E. Molzahn, M. Kalfoss, Quality of life of older adults in Canada and
Norway: examining the Iowa model, West. J. Nurs. Res. 30 (2008) 458–476.
[36] L.R. Derogatis, N. Melisaratos, The brief symptom inventory: an introductory re-
port, Psychol. Med. 13 (1983) 595–605.
[37] K.K. Morian, S.Y. Tan, Comparison of the brief psychiatric rating scale and the brief
symptom inventory, J. Clin. Psychol. 54 (1998) 885–894.
[38] E. de Beurs, Brief Symptom Inventory Handleiding, revised ed., PITS BV, Leiden,
2011.
[39] F. Sterk, M.M. Rijkeboer, Schema-vragenlijst [schema-Questionnaire],
Ambulatorium Utrecht University, Utrecht, 1997.
[40] M.M. Rijkeboer, H. van den Bergh, Multiple group confirmatory factor analysis of
the Young Schema-Questionnaire in a Dutch clinical versus non-clinical population,
Cognit. Ther. Res. 30 (2006) 263–278.
[41] E. Pauwels, L. Claes, E. Dierckx, I. Debast, S.P.J. van Alphen, G. Rossi, C. Schotte,
E. Santens, H. Peuskens, Age neutrality of the Young Schema Questionnaire in
patients with a substance use disorder, Int. Psychogeriatr. 26 (2014) 1317–1326.
[42] J. Lobbestael, M. van Vreeswijk, P. Spinhoven, E. Schouten, A. Arntz, Reliability
and validity of the short schema mode inventory (SMI), Behav. Cognit. Psychother.
38 (2010) 437–458.
[43] A. Arntz, M. van den Hoorn, J. Cornelis, R. Verheul, W.M. van den Bosch, A.J. de
Bie, Reliability and validity of the borderline personality disorder severity index, J.
Pers. Disord. 17 (2003) 45–59.
[44] A. Weertman, A. Arntz, M.L.M. Kerkhofs, Gestructureerd Diagnostisch Interview
Voor DSM-IV Persoonlijkheidsstoornissen (SCID-II) [Structured Diagnostic
Interview for DSM-IV Personality Disorders], Swets Test Publishers, Lisse, 2000.
[45] J. Lobbestael, M. Leurgans, A. Arntz, Inter-rater reliability of the structured clinical
interview for DSM-IV Axis I disorders (SCID I) and Axis II disorders (SCID II), Clin.
Psychol. Psychother. 18 (2011) 75–79.
[46] R. Verheul, H. Andrea, C.C. Berghout, C. Dolan, J.J. Busschbach, P. van der Kroft,
P. Fonagy, Severity Indices of personality problems (SIPP-118): development, factor
structure, reliability, and validity, Psychol. Assess. 20 (2008) 23.
[47] P. van der Heijden, T. Ingenhoven, H. Berghuis, G. Rossi, DSM-5
Persoonlijkheidsvragenlijst [Dutch Version of the the Personality Inventory for
DSM–5], Boom, Amsterdam, 2015.
[48] J.E. Young, G. Fosse, Schema Therapy Rating Scale, Cognitive Therapy Center of
New York, New York, 2005.
[49] P. Onghena, B.S. Everitt, D.C. Howell, Single-case designs, Encyclopedia of Statistics
in Behavioral Science, vol. 4, 2005, pp. 1850–1854.
[50] A.C. Videler, C.M. van der Feltz-Cornelis, G. Rossi, R.J.J. van Royen, E. Rosowsky,
S.P.J. van Alphen, Psychotherapeutic treatment levels of personality disorders in
older adults, Clin. Gerontol. 38 (2015) 325–341.
[51] H.M. Nordahl, T.E. Nysæter, Schema therapy for patients with borderline person-
ality disorder: a single case series, J. Behav. Ther. Exp. Psychiatr. 36 (2005)
254–264.
[52] J.M. Farrell, I.A. Shaw, M.A. Webber, A schema-focused approach to group psy-
chotherapy for outpatients with borderline personality disorder: a randomized
controlled trial, J. Behav. Ther. Exp. Psychiatr. 40 (2009) 317–328.
D.A. Khasho et al. Contemporary Clinical Trials Communications 14 (2019) 100330
5
